Power3 Products
Power3 leverages its knowledge of proteomics to detect diseases earlier than currently thought possible. The focus of Power3's efforts is on developing very sensitive patient tests that will enable doctors to diagnose and treat a disease before it becomes life-threatening or debilitating. Below you will find information about the areas of specific focus:
F A C T S
Alzheimer's Disease:
Every 72 seconds someone in America will develop Alzheimer’s.
Current estimate that 5.1Million Americans have Alzheimer’s.
Almost 10 Million Americans caring for Alzheimer’s disease or related dementia
Medicare for AD beneficiaries will increase 75% in 5 yrs from 91B to 160B by 2010.
Average cost per nursing home per year $42000 - $72000 depending on the region
AD cost to US business per year $61 B
Early AD is subtle, the diagnosis continue to be missed:
-It is easy for family members to avoid the problem and compensate for the patient.
-Physicians tend to miss the initial signs and symptoms
Less than half of the AD patients are diagnosed:
- Estimated are that 25% to 50% of cases remain undiagnosed
- Diagnoses are missed at all levels of severity: Mild, Moderate and severe.
No definitive laboratory test for diagnosing AD exists:
- Efforts to develop biomarkers, early recognition by brain scan have not provided a screening methodology
World prevalence of Dementia was 24Million world wide in 2001, estimated to double ever 20 years reach 81 Million patients by 2040. Estimated Global cost of Dementia is $315B, $76B cost in US only. Alzheimer’s disease is one type of dementia.
Parkinson's Disease:
Prevalance of Parkinson's Disease: 1.5 million people (unreliable estimate)
Undiagnosed prevalence of Parkinson's Disease: estimated 3-4 million people
Undiagnosed prevalence rate: approx 1 in 90 or 1.10% or 3 million people in USA [about data]
Deaths from Parkinson's Disease: 14,593 deaths reported in USA 1999 (NVSR Sep 2001)
Death rate extrapolations for USA for Parkinson's Disease: 14,593 per year, 1,216 per month, 280 per week, 39 per day, 1 per hour, 0 per minute, 0 per second.
Breast Cancer:
1 in every 8 women will develop breast cancer
According to the World Health Organization, more than 1.2 million people will be diagnosed with breast cancer each year worldwide and over 500,000 will die from the disease. The American Cancer Society estimates that in US 180,510 new cases of invasive breast cancer will be diagnosed in 2007. About 40,910 breast cancer deaths are expected in 2007.
Approximately 77% of breast cancer cases occur in women over 50 years of age.
The Middle East Partnership for Breast Cancer Awareness and Research, launched in 2006, links U.S. research institutions with Middle Eastern counterparts.
Contrary to popular belief and assurances by the U. S. media - the National Cancer Institute (NCI) and American Cancer Society (ACS)- mammography is not a technique for early diagnosis. In fact, a breast cancer has usually been present for about eight –ten years before it can finally be detected.
Every year millions of American women undergo mammogram screening. Over a period of 10 years, half of those who have an annual mammogram will have a false positive finding. Of that number, 19% will also undergo biopsy.
Mistakenly diagnosed cancers are particularly common in premenopausal women, and also in postmenopausal women on estrogen replacement therapy, resulting in needless anxiety, more mammograms, and unnecessary biopsies.
Overdiagnosis and subsequent overtreatment are among the major risks of mammography.
In a recent nationwide survey of women, 99 percent of respondents were aware of the possibility of false positive results from mammography, but only 6 percent were aware of either DCIS by name or the fact that mammography could detect a form of 'cancer' that often doesn't progress".
Proteomics:
Proteomics is the global study of protein expression, regulation, modification, and function in living systems for understanding how living systems use proteins. Using a variety of techniques, proteomics can be used to study how protein interacts within a biological system or how proteins change in response to a certain stress conditions. Proteomics require the use of advanced measurement techniques with emphasis on separation and mass spectroscopy.